Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

If you feel like your turntable setup needs a refresh, it might be worth thinking about changing the current cartridge rather than swapping out an entire record player or amplifier. It's a simple but ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human ... Q and current reports on Form 8-K. You are cautioned not to place ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults ... and subsequent periodic reports on Form 10-Q ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only ...

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for adults with type 1 and type ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...